VERU INC (VERU) Stock Fundamental Analysis

NASDAQ:VERU • US92536C2026

2.49 USD
+0.07 (+2.89%)
Last: Feb 19, 2026, 08:00 PM
Fundamental Rating

2

Overall VERU gets a fundamental rating of 2 out of 10. We evaluated VERU against 191 industry peers in the Pharmaceuticals industry. The financial health of VERU is average, but there are quite some concerns on its profitability. VERU has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • VERU had negative earnings in the past year.
  • In the past year VERU has reported a negative cash flow from operations.
  • VERU had negative earnings in 4 of the past 5 years.
  • VERU had a negative operating cash flow in each of the past 5 years.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -76.17%, VERU is doing worse than 72.77% of the companies in the same industry.
  • With a Return On Equity value of -123.97%, VERU is not doing good in the industry: 65.97% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -76.17%
ROE -123.97%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • VERU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

6

2. Health

2.1 Basic Checks

  • VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VERU has about the same amount of shares outstanding.
  • VERU has more shares outstanding than it did 5 years ago.
  • VERU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -16.35, we must say that VERU is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of VERU (-16.35) is worse than 79.58% of its industry peers.
  • There is no outstanding debt for VERU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.35
ROIC/WACCN/A
WACC9.36%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 2.43 indicates that VERU has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.43, VERU perfoms like the industry average, outperforming 44.50% of the companies in the same industry.
  • A Quick Ratio of 2.43 indicates that VERU has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.43, VERU is in line with its industry, outperforming 50.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.43
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.38% over the past year.
EPS 1Y (TTM)55.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, VERU will show a small growth in Earnings Per Share. The EPS will grow by 3.67% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-44.5%
EPS Next 2Y-8.15%
EPS Next 3Y10.54%
EPS Next 5Y3.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2032 2033 20M 40M 60M 80M 100M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4 -6 -8 -10

0

4. Valuation

4.1 Price/Earnings Ratio

  • VERU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.15%
EPS Next 3Y10.54%

0

5. Dividend

5.1 Amount

  • VERU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

VERU INC

NASDAQ:VERU (2/19/2026, 8:00:01 PM)

2.49

+0.07 (+2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners22.05%
Inst Owner Change-20.2%
Ins Owners9.78%
Ins Owner Change0%
Market Cap39.96M
Revenue(TTM)N/A
Net Income(TTM)-22.73M
Analysts85
Price Target25.5 (924.1%)
Short Float %5.33%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.58%
Min EPS beat(2)8.08%
Max EPS beat(2)123.07%
EPS beat(4)4
Avg EPS beat(4)43.01%
Min EPS beat(4)8.08%
Max EPS beat(4)123.07%
EPS beat(8)6
Avg EPS beat(8)21.21%
EPS beat(12)8
Avg EPS beat(12)16.35%
EPS beat(16)9
Avg EPS beat(16)4.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.11%
PT rev (3m)17.65%
EPS NQ rev (1m)-36.89%
EPS NQ rev (3m)-24.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.18
P/tB 3.49
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)-1.75
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS0
BVpS1.14
TBVpS0.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.17%
ROE -123.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.43
Altman-Z -16.35
F-Score3
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.67%
EPS Next Y-44.5%
EPS Next 2Y-8.15%
EPS Next 3Y10.54%
EPS Next 5Y3.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.36%
OCF growth 3YN/A
OCF growth 5YN/A

VERU INC / VERU FAQ

Can you provide the ChartMill fundamental rating for VERU INC?

ChartMill assigns a fundamental rating of 2 / 10 to VERU.


Can you provide the valuation status for VERU INC?

ChartMill assigns a valuation rating of 0 / 10 to VERU INC (VERU). This can be considered as Overvalued.


What is the profitability of VERU stock?

VERU INC (VERU) has a profitability rating of 0 / 10.


Can you provide the financial health for VERU stock?

The financial health rating of VERU INC (VERU) is 6 / 10.